# Narration and storyboard draft: Partial Reprogramming and Human Aging

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Can partial reprogramming make human adults healthier for longer? The laboratory evidence is substantial enough to take seriously, and controlled human healthspan benefit remains unestablished. These statements belong together.

Researchers briefly express selected reprogramming factors or use chemical approaches to alter cellular state. Human fibroblast studies can reset selected epigenetic clocks, improve collagen production and change part of migration function. Their original Results also show temporary identity suppression, variable function that does not track clock changes, and some clocks that do not respond. A younger score is not the same as a younger person.

Animal function is real. Retinal OSK improves mouse vision in defined settings, with tests showing that DNA-demethylation pathways are necessary while demethylation alone is insufficient. Very-old male mice have improved remaining survival and frailty. That is remaining life, not twice the total lifespan. Treated human muscle cells have also been grafted into mice; human donors do not make the recipients human.

The human clinical-healthspan claim receives Gamma under HSEF v5.3, with moderate confidence. A separately declared preclinical proposition receives Epsilon because function and survival are causally changed in defined experimental contexts, with meaningful regimen boundaries. This supplemental judgment does not replace the human primary.

Clinical translation has begun in ER-100, an early ocular gene-therapy study. The sponsor has reported short-term signals in a very small open-label group. Those observations deserve follow-up but do not establish controlled durable benefit or broad safety.

Safety depends on factors, tissues, dose and duration. Some controlled partial protocols retain tested identity; other regimes can suppress it, cause organ failure or reach tumor-forming pluripotency. Neither a younger clock nor a short period without a tumor is a general safety certificate. The next decisive evidence needs objective human function, an appropriate comparator, independent assessment, validated clocks and long-term surveillance.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.